德琪醫藥-B(06996)：希維奧®在香港獲批用於治療多發性骨髓瘤及瀰漫大B細胞淋巴瘤兩種新增適應症

智通財經

12/03

智通財經APP訊，德琪醫藥-B(06996)公佈，香港特別行政區政府衛生署已批准希維奧^® (塞利尼索)的兩項補充新藥上市申請(sNDA)，批准希維奧^®聯合硼替佐米和地塞米松(XVd)用於治療既往接受過至少一種治療的多發性骨髓瘤(MM)成年患者;及希維奧^®作為單藥用於治療複發性或難治性瀰漫大B細胞淋巴瘤(rrDLBCL)成人患者，除另有說明外，其包含接受過至少兩線系統性治療且不符合造血幹細胞移植的由濾泡性淋巴瘤引起的瀰漫大B細胞淋巴瘤(DLBCL)。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588019668"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588019668\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588019668?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-03 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588019668","market":"sh","top_or_hot":-1,"title":"德琪醫藥-B(06996)：希維奧®在香港獲批用於治療多發性骨髓瘤及瀰漫大B細胞淋巴瘤兩種新增適應症","media":"智通財經","content":"<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/06996\">德琪醫藥-B</a>(06996)公佈，香港特別行政區政府衛生署已批准希維奧<sup>®</sup> (塞利尼索)的兩項補充新藥上市申請(sNDA)，批准希維奧<sup>®</sup>聯合硼替佐米和地塞米松(XVd)用於治療既往接受過至少一種治療的多發性骨髓瘤(MM)成年患者;及希維奧<sup>®</sup>作為單藥用於治療複發性或難治性瀰漫大B細胞淋巴瘤(rrDLBCL)成人患者，除另有說明外，其包含接受過至少兩線系統性治療且不符合造血幹細胞移植的由濾泡性淋巴瘤引起的瀰漫大B細胞淋巴瘤(DLBCL)。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德琪醫藥-B(06996)：希維奧®在香港獲批用於治療多發性骨髓瘤及瀰漫大B細胞淋巴瘤兩種新增適應症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德琪醫藥-B(06996)：希維奧®在香港獲批用於治療多發性骨髓瘤及瀰漫大B細胞淋巴瘤兩種新增適應症\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-12-03 16:38</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/06996\">德琪醫藥-B</a>(06996)公佈，香港特別行政區政府衛生署已批准希維奧<sup>®</sup> (塞利尼索)的兩項補充新藥上市申請(sNDA)，批准希維奧<sup>®</sup>聯合硼替佐米和地塞米松(XVd)用於治療既往接受過至少一種治療的多發性骨髓瘤(MM)成年患者;及希維奧<sup>®</sup>作為單藥用於治療複發性或難治性瀰漫大B細胞淋巴瘤(rrDLBCL)成人患者，除另有說明外，其包含接受過至少兩線系統性治療且不符合造血幹細胞移植的由濾泡性淋巴瘤引起的瀰漫大B細胞淋巴瘤(DLBCL)。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1377039.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06996","symbol_name":"德琪醫藥-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1377039.html","article_id":"2588019668","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588019668","pubTimestamp":1764751139,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP訊，德琪醫藥-B(06996)公佈，香港特別行政區政府衞生署已批准希維奧® (塞利尼索)的兩項補充新藥上市申請(sNDA)，批准希維奧®聯合硼替佐米和地塞米松(XVd)用於治療既往接受過至少一種治療的多發性骨髓瘤(MM)成年患者;及希維奧®作為單藥用於治療複發性或難治性瀰漫大B細胞淋巴瘤(rrDLBCL)成人患者，除另有説明外，其包含接受過至少兩線系統性治療且不符合造血幹細胞移植的由濾泡性淋巴瘤引起的瀰漫大B細胞淋巴瘤(DLBCL)。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06996":"德琪医药-B","BK1574":"生物医药B类股","BK1191":"制药","BK1583":"高瓴概念"},"translate_title":"Antengene-B (06996): Sivio ® Approved in Hong Kong for the treatment of multiple myeloma and diffuse large B-cell lymphoma in two new indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1.5},"content_text":"智通財經APP訊，德琪醫藥-B(06996)公佈，香港特別行政區政府衞生署已批准希維奧® (塞利尼索)的兩項補充新藥上市申請(sNDA)，批准希維奧®聯合硼替佐米和地塞米松(XVd)用於治療既往接受過至少一種治療的多發性骨髓瘤(MM)成年患者;及希維奧®作為單藥用於治療複發性或難治性瀰漫大B細胞淋巴瘤(rrDLBCL)成人患者，除另有説明外，其包含接受過至少兩線系統性治療且不符合造血幹細胞移植的由濾泡性淋巴瘤引起的瀰漫大B細胞淋巴瘤(DLBCL)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}